Retlirafusp Alfa
drug drugOn this page
Also known as Shr 1701SHR-1701SHR1701
Summary
Retlirafusp Alfa (CHEMBL5095383) is a phase-3 clinical-stage protein; indicated across 10 conditions including non-small cell lung carcinoma and head and neck squamous cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 10 conditions
- Clinical trials: 38
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095383 |
| Name | Retlirafusp Alfa |
| Type | Protein |
| Max phase | 3 |
Also known as: Retlirafusp alfa, Shr 1701, SHR-1701, SHR1701, RETLIRAFUSP ALFA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| exocrine pancreatic carcinoma | 1 | MONDO:0005192 | EFO:0002618 |
| Hodgkins lymphoma | 1 | MONDO:0004952 | EFO:0000183 |
| nasopharyngeal carcinoma | 1 | MONDO:0015459 | MONDO:0015459 |
Clinical trials
Total trials: 38.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 26 |
| PHASE1/PHASE2 | 5 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05149807 | PHASE2/PHASE3 | TERMINATED | Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer |
| NCT05671822 | PHASE2 | RECRUITING | Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer |
| NCT05896046 | PHASE1/PHASE2 | RECRUITING | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma |
| NCT06679673 | PHASE2 | NOT_YET_RECRUITING | SHR-1701 Combined with SHR2554 and BP102 for MCRC |
| NCT06881017 | PHASE2 | NOT_YET_RECRUITING | Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping |
| NCT07102901 | PHASE2 | RECRUITING | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma |
| NCT07147088 | PHASE2 | NOT_YET_RECRUITING | Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. |
| NCT07175220 | PHASE2 | RECRUITING | Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects |
| NCT07294664 | PHASE2 | RECRUITING | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer |
| NCT07311408 | PHASE2 | RECRUITING | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure |
| NCT07355010 | PHASE2 | NOT_YET_RECRUITING | A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer |
| NCT07384234 | PHASE2 | NOT_YET_RECRUITING | SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis |
| NCT07451795 | PHASE2 | RECRUITING | SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC |
| NCT07464756 | PHASE2 | NOT_YET_RECRUITING | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer |
| NCT07478731 | PHASE2 | RECRUITING | Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer |
| NCT07503639 | PHASE2 | NOT_YET_RECRUITING | Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer |
| NCT07517653 | PHASE2 | NOT_YET_RECRUITING | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma |
| NCT07524374 | PHASE2 | NOT_YET_RECRUITING | SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy |
| NCT07607210 | PHASE2 | NOT_YET_RECRUITING | A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction |
| NCT07610629 | PHASE2 | NOT_YET_RECRUITING | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer |
| NCT04355858 | PHASE2 | UNKNOWN | Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer |
| NCT04407741 | PHASE1/PHASE2 | UNKNOWN | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas |
| NCT04560244 | PHASE2 | UNKNOWN | A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment |
| NCT04580498 | PHASE2 | UNKNOWN | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC |
| NCT04624217 | PHASE1/PHASE2 | COMPLETED | A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer |
| NCT04650633 | PHASE2 | UNKNOWN | SHR-1701 in Patients With Recurrent/Metastatic Scchn |
| NCT04679038 | PHASE1/PHASE2 | UNKNOWN | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors |
| NCT04699968 | PHASE2 | WITHDRAWN | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC |
| NCT04884009 | PHASE2 | UNKNOWN | A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer |
| NCT05020925 | PHASE1/PHASE2 | UNKNOWN | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma |
| NCT05106023 | PHASE2 | UNKNOWN | To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma |
| NCT05177497 | PHASE2 | UNKNOWN | SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC |
| NCT07581574 | PHASE1 | NOT_YET_RECRUITING | Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma |
| NCT03710265 | PHASE1 | UNKNOWN | SHR-1701 in Metastatic or Locally Advanced Solid Tumors |
| NCT03774979 | PHASE1 | UNKNOWN | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors |
| NCT04282070 | PHASE1 | UNKNOWN | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma |
| NCT04324814 | PHASE1 | COMPLETED | A Trial of SHR-1701 in Subjects With Advanced Solid Tumors |
| NCT06893887 | Not specified | RECRUITING | Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: non-small cell lung carcinoma, head and neck squamous cell carcinoma, melanoma, breast neoplasm, lung neoplasm